FAST NEWS: Legend Biotech Pares Losses on Milestone Revenue
The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), reported a loss of $41.09 million in the first quarter, half the $80.9 million loss from the same…
Recent Articles
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
1548.HK LEGN.US
-
Legend Holdings shows diversification isn’t always a winning formula
3396.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
Discover hidden China stock gems in our weekly newsletter